Vor Biopharma (NASDAQ:VOR) & Inhibikase Therapeutics (NASDAQ:IKT) Critical Review

Vor Biopharma (NASDAQ:VOR) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Profitability

This table compares Vor Biopharma and Inhibikase Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Inhibikase Therapeutics	N/A	-63.82%	-58.03%

Institutional and Insider Ownership

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 0.5% of Vor Biopharma shares are held by company insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Vor Biopharma and Inhibikase Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	($273.20)	-0.10
Inhibikase Therapeutics	$260,000.00	447.12	-$27.52 million	($0.91)	-1.71

Vor Biopharma has higher earnings, but lower revenue than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Vor Biopharma and Inhibikase Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	2	3	5	1	2.45
Inhibikase Therapeutics	1	0	0	0	1.00

Vor Biopharma currently has a consensus price target of $77.83, indicating a potential upside of 176.69%. Given Vor Biopharma’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Vor Biopharma is more favorable than Inhibikase Therapeutics.

Risk and Volatility

Vor Biopharma has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500.

Summary

Vor Biopharma beats Inhibikase Therapeutics on 9 of the 12 factors compared between the two stocks.

About Vor Biopharma

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company’s eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.